Background: Primary Immunodeficiencies (PIDs) are a heterogeneous group of genetic immune disorders. While some PIDs can manifest with more than one phenotype, signs, and symptoms of various PIDs overlap considerably. Recently, novel defects in immune-related genes and additional variants in previously reported genes responsible for PIDs have been successfully identified by Next Generation Sequencing (NGS), allowing the recognition of a broad spectrum of disorders. Objective: To evaluate the strength and weakness of targeted NGS sequencing using custom-made Ion Torrent and Haloplex (Agilent) panels for diagnostics and research purposes. Methods: Five different panels including known and candidate genes were used to screen 105 patients with distinct PID features divided in three main PID categories: T cell defects, Humoral defects and Other PIDs. The Ion Torrent sequencing platform was used in 73 patients. Among these, 18 selected patients without a molecular diagnosis and 32 additional patients were analyzed by Haloplex enrichment technology. Results: The complementary use of the two custom-made targeted sequencing approaches allowed the identification of causative variants in 28.6% (n = 30) of patients. Twenty-two out of 73 (34.6%) patients were diagnosed by Ion Torrent. In this group 20 were included in the SCID/CID category. Eight out of 50 (16%) patients were diagnosed by Haloplex workflow. Ion Torrent method was highly successful for those cases with well-defined phenotypes for immunological and clinical presentation. The Haloplex approach was able to diagnose 4 SCID/CID patients and 4 additional patients with complex and extended phenotypes, embracing all three PID categories in which this approach was more efficient. Both technologies showed good gene coverage. Conclusions: NGS technology represents a powerful approach in the complex field of rare disorders but its different application should be weighted. A relatively small NGS target panel can be successfully applied for a robust diagnostic suspicion, while when the spectrum of clinical phenotypes overlaps more than one PID an in-depth NGS analysis is required, including also whole exome/genome sequencing to identify the causative gene.

Targeted NGS platforms for genetic screening and gene discovery in primary immunodeficiencies / Cifaldi, C.; Brigida, I.; Barzaghi, F.; Zoccolillo, M.; Ferradini, V.; Petricone, D.; Cicalese, M. P.; Lazarevic, D.; Cittaro, D.; Omrani, M.; Attardi, E.; Conti, F.; Scarselli, A.; Chiriaco, M.; Di Cesare, S.; Licciardi, F.; Davide, M.; Ferrua, F.; Canessa, C.; Pignata, C.; Giliani, S.; Ferrari, S.; Fousteri, G.; Barera, G.; Merli, P.; Palma, P.; Cesaro, S.; Gattorno, M.; Trizzino, A.; Moschese, V.; Chini, L.; Villa, A.; Azzari, C.; Finocchi, A.; Locatelli, F.; Rossi, P.; Sangiuolo, F.; Aiuti, A.; Cancrini, C.; Di Matteo, G.. - In: FRONTIERS IN IMMUNOLOGY. - ISSN 1664-3224. - 10:APR(2019). [10.3389/fimmu.2019.00316]

Targeted NGS platforms for genetic screening and gene discovery in primary immunodeficiencies

Locatelli F.;
2019

Abstract

Background: Primary Immunodeficiencies (PIDs) are a heterogeneous group of genetic immune disorders. While some PIDs can manifest with more than one phenotype, signs, and symptoms of various PIDs overlap considerably. Recently, novel defects in immune-related genes and additional variants in previously reported genes responsible for PIDs have been successfully identified by Next Generation Sequencing (NGS), allowing the recognition of a broad spectrum of disorders. Objective: To evaluate the strength and weakness of targeted NGS sequencing using custom-made Ion Torrent and Haloplex (Agilent) panels for diagnostics and research purposes. Methods: Five different panels including known and candidate genes were used to screen 105 patients with distinct PID features divided in three main PID categories: T cell defects, Humoral defects and Other PIDs. The Ion Torrent sequencing platform was used in 73 patients. Among these, 18 selected patients without a molecular diagnosis and 32 additional patients were analyzed by Haloplex enrichment technology. Results: The complementary use of the two custom-made targeted sequencing approaches allowed the identification of causative variants in 28.6% (n = 30) of patients. Twenty-two out of 73 (34.6%) patients were diagnosed by Ion Torrent. In this group 20 were included in the SCID/CID category. Eight out of 50 (16%) patients were diagnosed by Haloplex workflow. Ion Torrent method was highly successful for those cases with well-defined phenotypes for immunological and clinical presentation. The Haloplex approach was able to diagnose 4 SCID/CID patients and 4 additional patients with complex and extended phenotypes, embracing all three PID categories in which this approach was more efficient. Both technologies showed good gene coverage. Conclusions: NGS technology represents a powerful approach in the complex field of rare disorders but its different application should be weighted. A relatively small NGS target panel can be successfully applied for a robust diagnostic suspicion, while when the spectrum of clinical phenotypes overlaps more than one PID an in-depth NGS analysis is required, including also whole exome/genome sequencing to identify the causative gene.
2019
gene panels; haloplex; ion torrent; next generation sequencing; primary immunodeficiencies
01 Pubblicazione su rivista::01a Articolo in rivista
Targeted NGS platforms for genetic screening and gene discovery in primary immunodeficiencies / Cifaldi, C.; Brigida, I.; Barzaghi, F.; Zoccolillo, M.; Ferradini, V.; Petricone, D.; Cicalese, M. P.; Lazarevic, D.; Cittaro, D.; Omrani, M.; Attardi, E.; Conti, F.; Scarselli, A.; Chiriaco, M.; Di Cesare, S.; Licciardi, F.; Davide, M.; Ferrua, F.; Canessa, C.; Pignata, C.; Giliani, S.; Ferrari, S.; Fousteri, G.; Barera, G.; Merli, P.; Palma, P.; Cesaro, S.; Gattorno, M.; Trizzino, A.; Moschese, V.; Chini, L.; Villa, A.; Azzari, C.; Finocchi, A.; Locatelli, F.; Rossi, P.; Sangiuolo, F.; Aiuti, A.; Cancrini, C.; Di Matteo, G.. - In: FRONTIERS IN IMMUNOLOGY. - ISSN 1664-3224. - 10:APR(2019). [10.3389/fimmu.2019.00316]
File allegati a questo prodotto
File Dimensione Formato  
Cifaldi_Targeted-NGS_2019.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1.6 MB
Formato Adobe PDF
1.6 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1480030
Citazioni
  • ???jsp.display-item.citation.pmc??? 20
  • Scopus 32
  • ???jsp.display-item.citation.isi??? 33
social impact